Management of Treatment-Resistant Childhood Mood and Anxiety Disorders

2016 ◽  
Vol 69 (5-6) ◽  
pp. 171-176 ◽  
Author(s):  
Dusan Kolar ◽  
Michael Kolar

Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Benzodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating major depressive disorder but without sustained benefits. Long-term use may pose a significant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds more as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions, but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropri?ateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.


PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0204925 ◽  
Author(s):  
Nina K. Vollbehr ◽  
Agna A. Bartels-Velthuis ◽  
Maaike H. Nauta ◽  
Stynke Castelein ◽  
Laura A. Steenhuis ◽  
...  

2011 ◽  
Author(s):  
D. Ryan Hooper ◽  
Michael J. Ross ◽  
Jillon S. Vander Wal ◽  
Terri L. Weaver

2019 ◽  
Vol 42 (2) ◽  
pp. 158-168
Author(s):  
Janie Houle ◽  
Stephanie Radziszewski ◽  
Préscilla Labelle ◽  
Simon Coulombe ◽  
Matthew Menear ◽  
...  

2001 ◽  
Author(s):  
David J. Nutt ◽  
Caroline Bell ◽  
Christine Masterson ◽  
Clare Short

Author(s):  
Hailey Saunders ◽  
Elizabeth Osuch ◽  
Kelly Anderson ◽  
Janet Martin ◽  
Abraham Kunnilathu ◽  
...  

2021 ◽  
Vol 30 ◽  
Author(s):  
Jordan Edwards ◽  
A. Demetri Pananos ◽  
Amardeep Thind ◽  
Saverio Stranges ◽  
Maria Chiu ◽  
...  

Abstract Aims There is currently no universally accepted measure for population-based surveillance of mood and anxiety disorders. As such, the use of multiple linked measures could provide a more accurate estimate of population prevalence. Our primary objective was to apply Bayesian methods to two commonly employed population measures of mood and anxiety disorders to make inferences regarding the population prevalence and measurement properties of a combined measure. Methods We used data from the 2012 Canadian Community Health Survey – Mental Health linked to health administrative databases in Ontario, Canada. Structured interview diagnoses were obtained from the survey, and health administrative diagnoses were identified using a standardised algorithm. These two prevalence estimates, in addition to data on the concordance between these measures and prior estimates of their psychometric properties, were used to inform our combined estimate. The marginal posterior densities of all parameters were estimated using Hamiltonian Monte Carlo (HMC), a Markov Chain Monte Carlo technique. Summaries of posterior distributions, including the means and 95% equally tailed posterior credible intervals, were used for interpretation of the results. Results The combined prevalence mean was 8.6%, with a credible interval of 6.8–10.6%. This combined estimate sits between Bayesian-derived prevalence estimates from administrative data-derived diagnoses (mean = 7.4%) and the survey-derived diagnoses (mean = 13.9%). The results of our sensitivity analysis suggest that varying the specificity of the survey-derived measure has an appreciable impact on the combined posterior prevalence estimate. Our combined posterior prevalence estimate remained stable when varying other prior information. We detected no problematic HMC behaviour, and our posterior predictive checks suggest that our model can reliably recreate our data. Conclusions Accurate population-based estimates of disease are the cornerstone of health service planning and resource allocation. As a greater number of linked population data sources become available, so too does the opportunity for researchers to fully capitalise on the data. The true population prevalence of mood and anxiety disorders may reside between estimates obtained from survey data and health administrative data. We have demonstrated how the use of Bayesian approaches may provide a more informed and accurate estimate of mood and anxiety disorders in the population. This work provides a blueprint for future population-based estimates of disease using linked health data.


Sign in / Sign up

Export Citation Format

Share Document